Treatment of bicalutamide-induced breast events

References

• Wirth MP, See WA, McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at medial followup of 5.4 years. J. Urol.172, 1865–1870 (2004).
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med.341, 1781–1788 (1999).
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomized trial. Lancet360, 103–106 (2002).
   PubMed Web of Science ®Google Scholar
• Kaisary AV. Evaluating the use of early hormonal therapy in patients with localized or locally advanced prostate cancer. Prostate Cancer Prostatic Dis.8(2), 140–151 (2005).
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA. Treatment of locally advanced prostate cancer – a new role for antiandrogen monotherapy? Eur. Urol.39(Suppl. 1), 22–28 (2001).
   Google Scholar
• Anderson J. Quality of life aspects of treatment options for localized and locally advanced prostate cancer. Eur. Urol.40(Suppl. 2), 24–30 (2001).
   Google Scholar
• Wellington K, Keam SJ. Bicalutamide: a review of its use in the treatment of locally advanced prostate cancer. Drugs66(6), 837–850 (2006).
   Google Scholar
• DiLorenzo G, Autorino R, Perdona S, De Placido S. Management of gynecomastia in patients with prostate cancer: a systematic review. Lancet Oncol.6, 972–979 (2005).
   Google Scholar
• Autorino R, Perdonà S, D’Armiento M et al. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis.9, 109–114 (2006).
   Google Scholar
• Dobs A, Darkes M. Incidence and management of gynecomastia in men treated for prostate cancer. J. Urol.174, 1737–1742 (2005).
   PubMed Web of Science ®Google Scholar
• Sieber PR, Keiller DL, Kahnoski RJ et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J. Urol.171, 2272–2276 (2004).
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol.164, 1579–1582 (2000).
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology51(3), 389–396 (1998).
   PubMed Web of Science ®Google Scholar
• See W, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J. Urol.168, 429–435 (2002).
   PubMed Web of Science ®Google Scholar
• Iversen P, Johansson JE, Lodding P et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group study number 6. J. Urol.172, 1871–1876 (2004).
   PubMed Web of Science ®Google Scholar
• Wirth MP, See WA, McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol.172, 1865–1870 (2004).
   PubMed Web of Science ®Google Scholar
• Decensi AU, Boccardo F, Guarneri D et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J. Urol.146(2), 377–381 (1991).
   PubMed Web of Science ®Google Scholar
• Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology48(6), 901–905 (1996).
   PubMed Web of Science ®Google Scholar
• Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology62(5), 872–876 (2003).
   Google Scholar
• Gillat D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J. Cancer Res. Clin. Oncol.132(Suppl. 1), S17–S26 (2006).
   Google Scholar
• See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J. Cancer Res. Clin. Oncol.132(Suppl. 1), S7–S16 (2006).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Kelly WK. High-dose bicalutamide after radiotherapy for locally advanced prostate cancer; a standard of care? Nat. Clin. Pract. Urol.4(3), 134–135 (2007).
   Google Scholar
• Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis.8, 75–83 (2005).
   PubMed Web of Science ®Google Scholar
• Fradet Y, Egerdie B, Andersen M et al. Tamoxifen as prophylaxis for prevention of gynecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomized, placebo-controlled dose–response study. Eur. Urol.52(1), 106–115 (2007).
   PubMedGoogle Scholar
• Boccardo F, Rubagotti A, Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy or prostate cancer. J. Clin. Oncol.23(4), 808–815 (2005).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdonà S, De Placido S et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J. Urol.174, 2197–2203 (2005).
   PubMed Web of Science ®Google Scholar
• Perdonà S, Autorino R, De Placido S et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynecomastia and breast pain caused by bicalutamide in prostate cancer: a randomized controlled trial. Lancet Oncol.6(5), 295–300 (2005).
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Tyrrell CJ, Haustermans K et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynecomastia and breast pain in prostate cancer. Eur. Urol.47(5), 587–592 (2004).
   Google Scholar
• Tyrrell CJ, Payne H, Tammela TL et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int. J. Radiat. Oncol. Biol. Phys.60(2), 476–483 (2004).
   PubMed Web of Science ®Google Scholar
• Widmark A. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/ SFUO-3. Urology61(1), 145–151 (2003).
   Google Scholar
• Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism35, 705–708 (1986).
   PubMed Web of Science ®Google Scholar
• Alagaratnam TT. Idiopathic gynecomastia treated with tamoxifen: a preliminary report. Clin. Ther.9(5), 483–487 (1987).
   PubMed Web of Science ®Google Scholar
• McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med. J.83, 1283–1285 (1990).
   Google Scholar
• Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology50(6), 929–933 (1997).
   PubMed Web of Science ®Google Scholar
• Serels S, Melman A. Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation. J. Urol.159, 1309 (1998).
   Google Scholar
• Eaton A, Markis A, Markis A et al. Once weekly tamoxifen in the prevention of gynecomastia and breast pain secondary to bicalutamide therapy. J. Urol. (Suppl. 171), 282 (2004).
   Google Scholar
• Boccardo F, Rubagotti A, Battaglia M et al. Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. Int. J. Biol. Markers21(2), 123–126 (2006).
   Google Scholar
• Smith M, Chu F, Forrest J et al. Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raising HDL in prostate cancer patients on androgen deprivation therapy. 2007 ASCO Annual Meeting Proceedings25(Pt 1) S18 (2007).
   Google Scholar
• Pyrhönen S, Ellmén J, Vuorinen J et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat.56(2), 133–143 (1999).
   PubMed Web of Science ®Google Scholar
• Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast15(2), 142–157 (2006).
   PubMed Web of Science ®Google Scholar
• Ellmén J, Hakulinen P, Partanen A, Hayes DF. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. Treat.82(2), 103–111 (2003).
   PubMed Web of Science ®Google Scholar
• Kusama M, Miyauchi K, Aoyama H. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res. Treat.88(1), 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol.24(27), 4448–4456 (2006).
   PubMed Web of Science ®Google Scholar
• Braunstein GD. Aromatase and gynecomastia. Endocr. Relat. Cancer6, 315–324 (1999).
   PubMed Web of Science ®Google Scholar
• Gagnon JD, Moss WT, Stevens KR. Pre-estrogen breast irradiation for patients with carcinoma of the prostate: a critical review. J. Urol.121, 182–184 (1979).
   Google Scholar
• Waterfall NB, Glaser MG. A study of the effects of radiation on prevention of gynecomastia due to estrogen therapy. Clin. Oncol.5, 257–260 (1979).
   Google Scholar
• Fass D, Steinfeld A, Brown J, Tessler A. Radiotherapeutic prophylaxis of estrogen-induced gynecomastia: a study of late sequela. Int. J. Radiat. Oncol. Biol. Phys.12(3), 407–408 (1986).
   Google Scholar
• Chou JL, Easley JD, Feldmeier JJ, Rauth VA, Pomeroy TC. Effective radiotherapy in palliating mammalgia associated with gynecomastia after DES therapy. J. Radiat. Oncol. Biol. Phys.15, 749–751 (1988).
   Google Scholar